Search
Search
Show Description +
Dr. Marla B. Sultan, global clinical lead for MACUGEN at Pfizer, discusses the results from a Phase 3 study demonstrating MACUGEN (pegaptanib sodium) significantly improved vision in patients with diabetic macular edema (DME). The study was a multicenter, randomized, sham-controlled, double-masked, comparative Phase 3 trial over two years with an open-label year-three extension. The primary analysis included 260 patients with DME at 56 global sites. The primary objective of the study was to evaluate whether MACUGEN improved vision compared with sham injections in patients with DME, and to assess the safety of MACUGEN in these patients.
Posted: 7/01/2010
Dr. Marla B. Sultan, global clinical lead for MACUGEN at Pfizer, discusses the results from a Phase 3 study demonstrating MACUGEN (pegaptanib sodium) significantly improved vision in patients with diabetic macular edema (DME). The study was a multicenter, randomized, sham-controlled, double-masked, comparative Phase 3 trial over two years with an open-label year-three extension. The primary analysis included 260 patients with DME at 56 global sites. The primary objective of the study was to evaluate whether MACUGEN improved vision compared with sham injections in patients with DME, and to assess the safety of MACUGEN in these patients.
Posted: 7/01/2010
![[2019] Amniotic Membrane Placement for Repair of Recurrent Macular Hole](https://d33x7gwyb2b5z6.cloudfront.net/eyetube/thumbs/gldaw.jpg?auto=compress,format&w=180)
Please log in to leave a comment.